Table 2 Candidate target therapy according to genomic findings to gastric adenocarcinoma patients included in this study.
From: Socioeconomic disparities and the genomic landscape of gastric cancer
SES | Genomic findings | Drugs with clinical relevance in gastric cancer | Drugs with clinical relevance in other tumor types |
|---|---|---|---|
LSES | FBXW7-C46fs*14 | None | Everolimus, Temsirolimus |
ERBB2-G660D | Fam-trastuzumab deruxtecan, Trastuzumab | Ado-trastuzumab emtansine, Lapatinib, Neratinib, Trastuzumab+Pertuzumab | |
EGFR-amplification-equivocal | None | Afatinib, Cetuximab, Dacomitinib, Panitumumab | |
ERBB2-amplification | Trastuzumab, Fam-trastuzumab deruxtecan, Trastuzumab+Pembrolizumab | Ado-trastuzumab emtansine, Afatinib, Dacomitinib, Lapatinib, Margetuximab, Neratinib, Trastuzumab+Pertuzumab | |
MET-amplification | None | Cabozantinib, Capmatinib, Crizotinib, Tepotinib | |
ATM-R337H | None | Niraparib, Olaparib, Rucaparib, Talazoparib | |
EGFR-amplification | None | Afatinib, Cetuximab, Dacomitinib, Panitumumab | |
PALB2-S288fs*15 | None | Niraparib, Olaparib, Rucaparib, Talazoparib | |
PIK3CA-Q546R | None | Everolimus, Temsirolimus | |
MHSES | ATM-R337H | None | Niraparib, Olaparib, Rucaparib, Talazoparib |
BRCA1-loss exons 15–19 | None | Niraparib, Olaparib, Rucaparib, Talazoparib | |
FGFR2-S799fs*17 | None | Erdafitinib | |
NF1-I679fs*21 | None | Selumetinib, Trametinib | |
PIK3CA-H1047R, R93Q | None | Everolimus, Temsirolimus |
